Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
四川科倫博泰生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 6990)

VOLUNTARY ANNOUNCEMENT
INVESTIGATIONAL NEW DRUG APPROVAL FOR SKB103 BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

The board (the "**Board**") of directors ("**Directors**") of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "**Company**") is pleased to announce that the Investigational New Drug (IND) application for SKB103, its self-developed novel bispecific antibody-drug conjugate (bsADC) with combined Tumor-Associated Antigen-targeting and Immuno-Oncology mechanisms (TAA-programmed cell death ligand 1 (PD-L1)), has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the treatment of advanced solid tumors. The approval marks SKB103 as the Company's first TAA-PD-L1 bsADC candidate and its second bsADC program for tumor therapy to enter the clinical stage, following SKB571.

As one of the industry leaders in the ADC field, the Company has established a solid competitive advantage. Currently, the Company's self-developed trophoblast cell-surface antigen 2 (TROP2)-directed ADC and human epidermal growth factor receptor 2 (HER2)-directed ADC have been approved for marketing, demonstrating significant clinical efficacy and competitive differentiation. Focusing on advances in oncology therapeutics, the Company continues to expand its innovative layout by building a diversified pipeline covering cutting-edge therapies such as radionuclide drug conjugate (RDC) and bsADC and fully driving breakthroughs and innovations in existing cancer treatment paradigms.

About SKB103

SKB103 is a potential best-in-class novel TAA-PD-L1 bsADC developed using the Company's proprietary OptiDC™ platform. Designed as a single molecule, SKB103 is expected to realize targeted delivery of cytotoxic payloads to tumors and modulation of tumor immune microenvironment simultaneously. In preclinical studies, SKB103 demonstrated outstanding anti-tumor activity and a favorable safety profile. The therapeutic potential of SKB103 will support its subsequent clinical development.

RISK WARNING

SKB103 MAY NOT ULTIMATELY BE SUCCESSFULLY DEVELOPED AND COMMERCIALIZED. THE COMPANY'S SHAREHOLDERS AND POTENTIAL INVESTORS ARE REMINDED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY.

By order of the Board
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
LIU Gexin
Chairman of the Board and Non-executive Director

Hong Kong, March 24, 2026

As at the date of this announcement, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou as executive Director, Mr. LIU Sichuan, Mr. LAI Degui, Mr. FENG Hao, Ms. LIAO Yihong and Mr. ZENG Xuebo as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong as independent non-executive Directors.